The global Immuno-oncology cell therapies market size is valued at US$ 7.20 Bn in 2021, and it is expected to reach US$ 34.69 Bn in 2030 recording a promising CAGR of 20.4% from 2022 to 2030. Immuno-oncology cell therapies are a remarkably promising treatment for a different types of cancer patients. The approval of CAR-T cell therapy products represents one of the most significant breakthroughs in cancer since the introduction of chemotherapy. Immuno-oncology cell therapies are one of the fastest advancing technology along with huge research and development activities. The oncology market today could be quickly superseded by next generation therapies in the upcoming forecast period. The Immuno-oncology Cell Therapy market is driven by factors such as increasing research funding in the immune-oncology, rising prevalence of cancer and focus on research activities from government health institutions and pharma giants inImmuno-oncology therapy development.
The global immuno-oncology cell therapies market is classified based on therapy type and region. Based on the therapy type, the market is segmented into CAR-T Cells, NK & NKT Cells, TAA/TSA targeted T Cell, TCR T Cell, and Other Cell Therapies.
Geographically, the Americas dominate the immuno-oncology cell therapies market owing to high healthcare expenditure and the rise in awareness among people. Europe stands for the second position in the immuno-oncology cell therapies market. It is expected that the support provided by government bodies for research & development and increased clinical trial programs in healthcare is going to drive the market in the Europe region. The Asia Pacific is known to be the fastest-growing immuno-oncology cell therapies market leading to a huge patient pool, developing healthcare technology and improving healthcare expenditure. The Middle East & Africa has the lowest market for immuno-oncology cell therapies due to inadequate medical facilities and lack of technical knowledge.
Some of key the players involved in the clinical trials/R&D activities Immuno-oncology cell therapies market are Novartis, Juno Therapeutics, Agios Pharmaceutical, Atara Biotherapeutics, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd., Autolus Limited, Kite Pharma, Bellicum Pharmaceuticals, bluebird bio, Calibr, Carina Biotech, CARsgen Therapeutics, Celgene Corporation, Cellectis, Cell Medica, Editas Medicine, Allogene Therapeutics, Amgen, Cell Design Labs, Celularity, Celyad, Fate Therapeutics, Fortress Bio, Gilead Sciences, Sorrento Therapeutics, Inc., Ziopharm, JW Therapeutics, Medigene, MedisixTherapeutics, Lion TCR, Mustang Bio, Nanjing Legend Biotech, Precision Biosciences, Posedia Therapeutics, Zelluna Immunotherapy, and others.
